Enliven Therapeutics Inc. (ELVN) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Enliven Therapeutics Inc. (NASDAQ: ELVN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $45.08 (+0.67% 1D, market cap $3.30B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ELVN ranks #493 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELVN carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -26.2%. By comparison, BHC (Bausch Health Companies Inc.) holds a C+ grade (69/100 RQD, P/E 21.2x, ROIC 7.6%, cap $3.33B) and VKTX (Viking Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $3.38B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
Per ELVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672619), Enliven Therapeutics Inc. generated $0 in revenue, -$103.7M in net income, and -$70.3M in free cash flow against $476.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±9.2% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ELVN currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($48.41) and Max Pain ($47.33) forces dealer call-delta covering toward $65.44.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Enliven Therapeutics Inc. (ELVN) advanced +0.67% to $45.08, trading at 64% of its 52-week range ($14.78 – $62.32). Stretched risk/reward at current multiples (-26% return on capital) under elevated 10-year interest-rate pressure.
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $65 to $73.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ELVN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ELVN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Enliven Therapeutics Inc. (ELVN) ranks #493 by composite RQD confidence (41/100, grade D-) and #200 by equity capitalization ($3.30B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with ELVN at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELVN
ACTIVE
Enliven Therapeutics Inc. | D- | 41/100 | — | — | -26.2% | +0.67% | $3.30B | Benchmark Subject |
| BHC Bausch Health Companies Inc. | C+ | 69/100 | 21.2x | — | 7.6% | +28.76% | $3.33B | /bhc-vs-elvn → |
| VKTX Viking Therapeutics Inc. | D | 44/100 | — | — | -35.0% | +5.92% | $3.38B | /vktx-vs-elvn → |
| TLX Telix Pharmaceuticals Limited | D | 47/100 | — | — | — | +2.70% | $3.22B | /tlx-vs-elvn → |
| DYN Dyne Therapeutics Inc. | E | 28/100 | — | — | -35.0% | +0.35% | $3.18B | /dyn-vs-elvn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Enliven Therapeutics Inc. (ELVN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$103.7M, operating cash flow of -$70.3M, and free cash flow of -$70.3M (+3.9% YoY). On the balance sheet, ELVN closed FY2025 with $476.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$103.7M | -$70.3M | -$70.3M | $476.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$89.0M | -$73.2M | -$73.2M | $325.8M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$71.6M | -$61.3M | -$61.3M | — | — |
As of 2026-11-02, Enliven Therapeutics Inc. (NASDAQ: ELVN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $45.08 (+0.67% 1D, market cap $3.30B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ELVN ranks #493 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELVN carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -26.2%. By comparison, BHC (Bausch Health Companies Inc.) holds a C+ grade (69/100 RQD, P/E 21.2x, ROIC 7.6%, cap $3.33B) and VKTX (Viking Therapeutics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $3.38B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).
Per ELVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672619), Enliven Therapeutics Inc. generated $0 in revenue, -$103.7M in net income, and -$70.3M in free cash flow against $476.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ELVN last traded at $45.08 (+0.67% on volume of 909,486 shares), positioning the stock -6.88% below its 50-day simple moving average ($48.41) and +5.25% above its 200-day simple moving average ($42.83). Across its 52-week range of $14.78 to $62.32, ELVN sits at the 63.7% percentile with a 14-day RSI of 54.2 (NEUTRAL RANGE) and an implied next-earnings move of ±9.2% ($40.93 to $49.23).
Why ELVN Stock advanced +0.67% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-26% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).